SCHEDULE 13G/A: BlackRock Discloses 1.5% Passive Stake in Actinium Pharmaceuticals
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.5% passive beneficial ownership stake in Actinium Pharmaceuticals, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 462,969 shares of Actinium Pharmaceuticals, Inc. common stock.
- This represents 1.5% of the total outstanding common stock of Actinium Pharmaceuticals, Inc.
- The filing indicates that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- BlackRock, Inc. has sole voting power over 461,305 shares and sole dispositive power over 462,969 shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a neutral sentiment as it provides no performance or strategic updates for the issuer.
Positives
- BlackRock, a major institutional investor, holds a stake in Actinium Pharmaceuticals, indicating some level of institutional interest.
- The filing confirms the shares are held for investment purposes in the ordinary course of business, not for control-related activities.
Negatives
- The reported stake of 1.5% is relatively small, suggesting a limited conviction or a passive index-tracking position rather than a significant strategic investment.
Future Outlook
This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Actinium Pharmaceuticals, Inc.'s future operations or financial performance.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing is a routine disclosure of a passive investment by a large asset manager, BlackRock, in a pharmaceutical company. It does not provide specific insights into broader industry trends or competitive dynamics within the pharmaceutical sector, beyond indicating BlackRock's presence as a shareholder.
Comparison to Industry Standards
- This filing is a standard beneficial ownership disclosure. It does not contain information for direct comparison to specific comparable companies, projects, or results within the pharmaceutical industry, as it focuses solely on BlackRock's ownership stake rather than Actinium Pharmaceuticals' operational or financial performance.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake.
- Management: Awareness of BlackRock's passive ownership.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-06-30 | Date of event which requires filing of this statement for BlackRock, Inc.'s beneficial ownership. |
| 2025-07-16 | Date of signing of the Schedule 13G Amendment No. 1 by BlackRock, Inc. |
Keywords
BlackRock, Actinium Pharmaceuticals, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.